Skip to main content
Clinical Trials/JPRN-jRCT2031220036
JPRN-jRCT2031220036
Recruiting
Phase 2

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of FYU-981 in Hyperuricemic Pediatric Patients with or without Gout (Phase II Study)

Masahiko Fushimi0 sites30 target enrollmentApril 23, 2022

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Hyperuricemic pediatric patients with or without gout
Sponsor
Masahiko Fushimi
Enrollment
30
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 23, 2022
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Masahiko Fushimi

Eligibility Criteria

Inclusion Criteria

  • Hyperuricemic pediatric patients with or without gout
  • \-Serum urate level:
  • \>\= 7\.0 mg/dL in patients with history of gout, or
  • \>\= 8\.0 mg/dL in patients complicated with kidney disease, hypertension, diabetes, metabolic syndrome or ischemic heart disease, or
  • \>\= 9\.0 mg/dL in patients with not applicable the above

Exclusion Criteria

  • \-Gouty arthritis within two weeks before start of study treatment
  • \-Renal overload type of hyperuricemia
  • \-HbA1c: \>\= 9\.0%
  • \-Clinically significant cardiac, and hepatic disease
  • \-Kidney calculi or clinically significant urinary calculi
  • \-eGFR: \< 30 mL/min/1\.73 m^2
  • \-AST: \>3xULN (upper limit of normal) or ALT: \>3xULN
  • \-Systolic blood pressure: \>\= 180 mmHg or diastolic blood pressure: \>\= 110 mmHg

Outcomes

Primary Outcomes

Not specified

Similar Trials